Asset Details
Do you wish to reserve the book?
Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration
Do you wish to request the book?
Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration
2020
Overview
Progressive multifocal leukoencephalopathy (PML) is a viral disease of the brain associated with immunodeficiency, immune suppressing medications, and malignancy. In the absence of effective anti-viral therapy for the causative JC virus, immune restoration has emerged as the critical therapeutic alternative. The evolving treatment of PML (and other rare JC virus–associated neurologic syndromes) requires consideration of baseline immune functioning and comorbid diseases while selecting from a number of therapeutic options to restore an effective immune response. This review focuses on the current options for management of PML in typical situations where this disease presents, including several where immune restoration is a standard therapeutic approach such as in PML associated with HIV/AIDS and in multiple sclerosis associated with natalizumab. Other circumstances in which PML occurs including associated with primary immunodeficiencies, malignancies, and transplants present greater challenges to immune reconstitution, but emerging concepts may enhance therapeutic options for these situations. Particular attention is focused on recent experience with checkpoint inhibitors, guidance for MS drug discontinuation, and strategies to monitor and facilitate immune restoration.
Publisher
Elsevier Inc,Springer International Publishing,Springer Nature B.V
Subject
/ Antibodies, Monoclonal, Humanized - administration & dosage
/ Antibodies, Monoclonal, Humanized - immunology
/ Biomedical and Life Sciences
/ HIV
/ Human immunodeficiency virus
/ Humans
/ Immune Reconstitution - immunology
/ Immunosuppressive Agents - administration & dosage
/ Immunosuppressive Agents - immunology
/ Leukoencephalopathy, Progressive Multifocal - immunology
/ Leukoencephalopathy, Progressive Multifocal - therapy
/ Natalizumab - administration & dosage
/ PML
/ Progressive multifocal leukoencephalopathy
/ therapy
